XEN723

Cat. No.: HY-100249

CAS No.: 1072803-08-7

Molecular Formula: $C_{21}H_{20}FN_5O_2S$

Molecular Weight: 425.48

Target: Stearoyl-CoA Desaturase (SCD)

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (235.03 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3503 mL	11.7514 mL	23.5029 mL
	5 mM	0.4701 mL	2.3503 mL	4.7006 mL
	10 mM	0.2350 mL	1.1751 mL	2.3503 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC_{50}s of 45 and 524 nM in mouse and HepG2 cell, respectively.

IC_{50} & Target

IC50: 45 nM (SCD1 in Mouse), 524 nM (SCD1 in HepG2 cell)[1]

In Vitro

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC_{50}s of 45 and 524 nM in mouse and HepG2 cell, respectively. XEN723 demonstrates an improvement in SCD1 in vitro potency of more than 560-fold compare to the original high throughput screen (HTS) hit[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sun S, et al. Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases. Bioorg Med Chem Lett. 2014 Jan 15;24(2):520-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA